Johnson & Johnson Stock Drops 063% Despite 1268 Billion Trading Volume Ranking 50th in Market Activity

On June 3, 2025, Johnson & Johnson (JNJ) experienced a trading volume of 12.68 billion, ranking 50th in the day's stock market activity. The stock price decreased by 0.63%.

Johnson & Johnson announced initial Phase 1 results of JNJ-79635322, a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. The trial demonstrated promising responses in heavily pretreated patients, with an overall response rate (ORR) of 86.1% among the 36 patients who received the recommended phase 2 dose (RP2D).

Among the 27 patients who were naive to certain treatments, the response rate was particularly notable. These early results are part of ongoing research, and the company cautions that these forward-looking statements should not be relied upon as predictions of future events.